---
title: "ABBISKO-B: The IND application for the oral PD-L1 inhibitor ABSK043 from ABBISKO Pharmaceuticals in combination with Allist's KRAS G12C inhibitor citric acid gorasib tablets for the treatment of NSCLC has been approved by CDE"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/253802893.md"
description: "ABBISKO-B announced that its subsidiary, ABBISKO Pharmaceuticals, has received approval from the Drug Evaluation Center of the National Medical Products Administration of China for the IND application of its oral PD-L1 inhibitor ABSK043 in combination with Allist's KRAS G12C inhibitor, citric acid gorasetinib tablets, for the treatment of KRAS G12C mutation non-small cell lung cancer. The two parties reached a cooperation agreement in March 2025 to conduct an open-label Phase II clinical study to evaluate the safety, tolerability, and efficacy of the combination therapy"
datetime: "2025-08-20T11:29:17.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/253802893.md)
  - [en](https://longbridge.com/en/news/253802893.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/253802893.md)
---

# ABBISKO-B: The IND application for the oral PD-L1 inhibitor ABSK043 from ABBISKO Pharmaceuticals in combination with Allist's KRAS G12C inhibitor citric acid gorasib tablets for the treatment of NSCLC has been approved by CDE

According to the Zhitong Finance APP, ABBISKO-B (02256) announced that its subsidiary, ABBISKO Pharmaceuticals, has received approval from the Drug Evaluation Center (CDE) of the National Medical Products Administration of China for the IND application of the oral PD-L1 inhibitor ABSK043 in combination with the KRAS G12C inhibitor citric acid gorasib tablets developed by Shanghai Allist Pharmaceutical Technology Co., Ltd. (Allist) for the treatment of patients with KRAS G12C mutation non-small cell lung cancer (NSCLC). In March 2025, ABBISKO Pharmaceuticals and Allist reached a cooperation agreement regarding the combination therapy of ABSK043 and citric acid gorasib tablets.

The approved study is "an open-label Phase II clinical study to evaluate the safety, tolerability, and efficacy of ABSK043 in combination with citric acid gorasib tablets in patients with locally advanced or metastatic NSCLC carrying KRAS G12C mutation."

### Related Stocks

- [688578.CN](https://longbridge.com/en/quote/688578.CN.md)
- [02256.HK](https://longbridge.com/en/quote/02256.HK.md)

## Related News & Research

- [Premium skincare brand Forest Cabin will study L’Oreal, but not copy it: CEO interview](https://longbridge.com/en/news/286831488.md)
- [Tencent Music completes $2.6 billion acquisition of podcast platform Ximalaya](https://longbridge.com/en/news/286841981.md)
- [US Senator Durbin urges RFK. Jr to resist easing vape rules](https://longbridge.com/en/news/287079463.md)
- [Trump signs order aimed at preventing illicit financial activity, White House says](https://longbridge.com/en/news/286970478.md)
- [ROI-Texas cuts gas use as ERCOT clean power momentum keeps growing: Maguire](https://longbridge.com/en/news/287164492.md)